ADJUVANT PAZOPANIB OR PLACEBO IN RESECTED STAGE I NSCLC PATIENTS: RESULTS OF THE NSCLC ADJUVANT RANDOMIZED PHASE II TRIAL (IFCT-0703) FROM THE FRENCH COLLABORATIVE INTERGROUP

被引：0

作者：

Besse, Benjamin ^{[1
]}

Mazieres, Julien ^{[2
]}

Ribassin-Majed, L. ^{[3
]}

Barlesi, Fabrice ^{[4
]}

Bennouna, Jaafar ^{[5
]}

Gervais, Radj ^{[6
]}

Moreau, Lionel

Berard, Henri ^{[7
]}

Debieuvre, Didier

Molinier, Olivier ^{[8
]}

Moro-Sibilot, Denis ^{[9
]}

Souquet, Pierre-Jean ^{[10
]}

Pignon, Jean-Pierre ^{[3
]}

Amour, Elodie ^{[11
]}

Celebic, A. ^{[3
]}

Morin, Franck ^{[11
]}

Milleron, Bernard ^{[11
]}

Zalcman, Gerard ^{[12
]}

Soria, Jean-Charles ^{[1
]}

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Univ Toulouse 3, Resp Med Serv, Hop Larrey, Chu Toulouse, F-31062 Toulouse, France

[3] Gustave Roussy, Biostat, Villejuif, France

[4] Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France

[5] Inst Cancerol Ouest, Gustave Roussy, France

[6] Ctr Francois Baclesse, Caen, France

[7] Hop Instruct Armees St Anne, Serv Pathol Resp, Toulon, France

[8] Le Mans Reg Hosp, Le Mans, France

[9] Unite Oncol Thorac Pneumol, Pierre Benite, France

[10] Pneumol Hcl, Paris, France

[11] Ifct, Paris, France

[12] Caen Univ Hosp, Caen, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

adjuvant; Non small cell lung cancer; angiogenic inhibitor; randomized phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO08.02

引用

页码：S301 / S301

页数：1

共 50 条

[31] The significance of K-ras mutations in the Intergroup JBR.10 Trial on adjuvant chemotherapy in completely resected early stage non-small cell lung cancer (NSCLC) patients
Tsao, M
Zhu, C
Livingston, R
Johnson, D
Gandara, D
Viallet, J
Ding, K
Seymour, L
Winton, T
Shepherd, F
LUNG CANCER, 2005, 49 : S41 - S41
[32] Surgical Factors and Adjuvant Therapy Use after Neoadjuvant Therapy for Patients with Resected Stage II-IIIB(N2) NSCLC
Stiles, B.
Chudgar, N. P.
Hu, X.
Kao, Y. -H.
Arunachalam, A.
Shariati, N. M.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S542 - S542
[33] Randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb): TREAT.
Kreuter, M.
Vansteenkiste, J. F.
Fischer, J. R.
Eberhardt, W. E. E.
Zabeck, H.
Kollmeier, J.
Serke, M. H.
Frickhofen, N.
Reck, M.
Engel-Riedel, W.
Neumann, S.
Thomeer, M.
Schumann, C.
Deleyn, P.
Graeter, T.
Stamatis, G.
Zuna, I.
Griesinger, F.
Thomas, M.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[34] A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10.
Winton, TL
Livingston, R
Johnson, D
Rigas, J
Cormier, Y
Butts, C
Ding, K
Seymour, L
Magoski, N
Shepherd, F
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 621S - 621S
[35] Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
Kirkwood, John
Del Vecchio, Michele
Weber, Jeffrey
Hoeller, Christoph
Grob, Jean-Jacques
Mohr, Peter
Loquai, Carmen
Dutriaux, Caroline
Chiarion-Sileni, Vanna
Mackiewicz, Jacek
Rutkowski, Piotr
Arenberger, Petr
Quereux, Gaelle
Meniawy, Tarek M.
Ascierto, Paolo A.
Menzies, Alexander M.
Durani, Piyush
Lobo, Maurice
Campigotto, Federico
Gastman, Brian
Long, Georgina V.
NATURE MEDICINE, 2023, 29 (11) : 2835 - 2843
[36] Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
John M. Kirkwood
Michele Del Vecchio
Jeffrey Weber
Christoph Hoeller
Jean-Jacques Grob
Peter Mohr
Carmen Loquai
Caroline Dutriaux
Vanna Chiarion-Sileni
Jacek Mackiewicz
Piotr Rutkowski
Petr Arenberger
Gaelle Quereux
Tarek M. Meniawy
Paolo A. Ascierto
Alexander M. Menzies
Piyush Durani
Maurice Lobo
Federico Campigotto
Brian Gastman
Georgina V. Long
Nature Medicine, 2023, 29 : 2835 - 2843
[37] Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
Motzer, Robert J.
Haas, Naomi B.
Donskov, Frede
Gross-Goupil, Marine
Varlamov, Sergei
Kopyltsov, Evgeny
Lee, Jae Lyun
Melichar, Bohuslav
Rini, Brian I.
Choueiri, Toni K.
Zemanova, Milada
Wood, Lori A.
Reaume, M. Neil
Stenzl, Arnulf
Chowdhury, Simon
Lim, Ho Yeong
McDermott, Ray
Michael, Agnieszka
Bao, Weichao
Carrasco-Alfonso, Marlene J.
Aimone, Paola
Voi, Maurizio
Doehn, Christian
Russo, Paul
Sternberg, Cora N.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (35) : 3916 - +
[38] A Randomised, Placebo-Controlled, Phase II Trial of Adjuvant Avelumab in Patients with Stage I-III Merkel Cell Carcinoma
Xu, Wen
Poulsen, Michael
Atkinson, Victoria
Fogarty, Gerald
Veness, Michael
Smithers, Bernard
Gyorki, David
Mar, Victoria
Guminski, Alexander
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 20 - 20
[39] The ASCENT Trial: A Phase II Study of Neoadjuvant/Adjuvant Afatinib, Chemoradiation plus /- Surgery for Stage III EGFR-Mutant NSCLC
Piper-Vallillo, A.
Mak, R.
Lanuti, M.
Muzikansky, A.
Rotow, J.
Janne, P.
Mino-Kenudson, M.
Swanson, S.
Wright, C.
Kozono, D.
Marcoux, J.
Piotrowska, Z.
Willers, H.
Sequist, L.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S188 - S188
[40] A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer
Miller, KD
Gradishar, W
Schuchter, L
Sparano, JA
Cobleigh, M
Robert, N
Rasmussen, H
Sledge, GW
ANNALS OF ONCOLOGY, 2002, 13 (08) : 1220 - 1224

← 1 2 3 4 5 →